drugset
Drugs / cemacabtagene ansegedleucel
last change Jul 2026 re-read 3 minutes ago

cemacabtagene ansegedleucel

also known as Cemacabtagen ansegedleucel

Cell therapy targets CD19

Developed for
large B-cell lymphoma
Investigated by
Allogene Therapeutics · Foresight Diagnostics, Inc. · Natera, Inc.

Trials 1

today NCT06500273 · Ph 2
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06500273 Jun 2024 → Dec 2027 expected large B-cell lymphoma Allogene Therapeutics Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 6

DateIssuerRelease
2026-07-29 Allogene Therapeutics Regulatory Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma allogene.com ↗
2026-05-13 Allogene Therapeutics Results Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update allogene.com ↗
Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma (LBCL)
2026-04-21 Allogene Therapeutics Regulatory Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia allogene.com ↗
2026-04-13 Allogene Therapeutics Results Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL allogene.com ↗
2025-08-01 Allogene Therapeutics Results Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma allogene.com ↗
Unplanned Review of Safety and Biomarker Data with Standard FC and Cema-cel Indicates Encouraging MRD Conversion Rate and Safety Profile
2025-02-13 Allogene Therapeutics Results Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology allogene.com ↗
These results represent the largest dataset of LBCL patients treated with an allogeneic CAR T product and, with a minimum of two years of follow-up, the longest follow-up to date.

All press releases naming this drug 9 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as cemacabtagene ansegedleucel ClinicalTrials.gov intervention name — accepted as the source's own label NCT06500273 ↗
Known as Cemacabtagen ansegedleucel ChEMBL registry synonym — accepted as the source's own label CHEMBL5314816 ↗
Modality Cell therapy “An allogeneic CAR T cell therapy targeting CD19” NCT06500273 ↗
Target CD19 “An allogeneic CAR T cell therapy targeting CD19” NCT06500273 ↗